CLINICAL_TRIALS
trial_result
· 2019-02-05
Clinical Trial Update: Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines [Phase 2]
Summary
Phase 2 safety study of DWP-450 (Botulinum purified neurotoxin type A) for treating glabellar lines completed with results posted in 2019.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Evolus, Inc. | Conditions: Glabellar Frown Lines | Phase 2 | Status: COMPLETED | Results posted: 2019-02-05